Immunological Medicine最新文献_第3页

Giant cell arteritis during risankizumab therapy: a possible paradoxical reaction to IL-23 inhibition. 利桑单抗治疗期间的巨细胞动脉炎：对IL-23抑制的可能矛盾反应。

IF 2.3

Immunological Medicine Pub Date : 2026-08-14 DOI: 10.1080/25785826.2026.2715180

Mai Sato, Hironobu Komine, Yasuo Nagafuchi, Shotaro Yamamoto, Jun Nakamura, Takeo Sato, Mamitaro Otsuki, Kojiro Sato

{"title":"Giant cell arteritis during risankizumab therapy: a possible paradoxical reaction to IL-23 inhibition.","authors":"Mai Sato, Hironobu Komine, Yasuo Nagafuchi, Shotaro Yamamoto, Jun Nakamura, Takeo Sato, Mamitaro Otsuki, Kojiro Sato","doi":"10.1080/25785826.2026.2715180","DOIUrl":"https://doi.org/10.1080/25785826.2026.2715180","url":null,"abstract":"Risankizumab is a selective interleukin (IL)-23p19 inhibitor used for psoriasis. Although IL-23 is implicated in giant cell arteritis (GCA), biologic therapy can occasionally be associated with paradoxical immune-mediated events. We report a 67-year-old woman who developed GCA during long-term risankizumab therapy for psoriasis vulgaris. She presented with progressive night sweats and fatigue, with marked systemic inflammation. Contrast-enhanced computed tomography and gadolinium-enhanced magnetic resonance imaging demonstrated large-vessel inflammation involving the aorta and its major branches. Temporal artery biopsy showed intimal hyperplasia, fragmentation of the internal elastic lamina, and mild inflammatory cell infiltration. She fulfilled the 2022 ACR/EULAR classification criteria for GCA and was treated with high-dose prednisolone, followed by methotrexate. Her symptoms and inflammatory markers improved rapidly, and risankizumab was continued because of excellent psoriasis control. Pretreatment serum cytokine analysis showed low IL-17 levels, whereas IFN-γ, IL-6, and TNF-α were comparable to or higher than those in other patients with GCA. This case highlights that GCA can develop during selective IL-23 blockade and may involve Th1-skewed inflammation or a paradoxical immune reaction.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-4"},"PeriodicalIF":2.3,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148762929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhibitory effect of iguratimod on Epstein-Barr virus production in Burkitt lymphoma cell line (AKATA) and B lymphoblastoid cells produced by in vitro transformation of Epstein-Barr virus. iguratimod对Burkitt淋巴瘤细胞株（AKATA）和eb病毒体外转化产生的B淋巴母细胞样细胞产生eb病毒的抑制作用

IF 2.3

Immunological Medicine Pub Date : 2026-08-11 DOI: 10.1080/25785826.2026.2712024

Noboru Kitamura, Yasuko Nagatsuka, Mitsuhiro Iwata, Masami Takei, Hideki Nakamura

{"title":"Inhibitory effect of iguratimod on Epstein-Barr virus production in Burkitt lymphoma cell line (AKATA) and B lymphoblastoid cells produced by in vitro transformation of Epstein-Barr virus.","authors":"Noboru Kitamura, Yasuko Nagatsuka, Mitsuhiro Iwata, Masami Takei, Hideki Nakamura","doi":"10.1080/25785826.2026.2712024","DOIUrl":"https://doi.org/10.1080/25785826.2026.2712024","url":null,"abstract":"Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) has been implicated in Epstein-Barr virus (EBV) reactivation. In this study, we aimed to investigate the role of iguratimod, an NF-κB activator inhibitor, in EBV lytic cycle activation in EBV-infected cells. EBV-producing cells, AKATA, and B-lymphoblastoid cells (BLBC) with 1 μM iguratimod. EBV DNA copy numbers were measured using real-time polymerase chain reaction. The inhibitory effect of iguratimod on NF-κB nuclear translocation in AKATA cells was examined. Immunohistochemical staining revealed significantly increased EBV early antigen diffuse type (EA-D) production in IgG-stimulated AKATA cells and IgM-stimulated BLBC compared with unstimulated cells, whereas co-culture with iguratimod suppressed the production of EBV EA-D. Additionally, AKATA cells/BLBC stimulated with anti-human IgG/IgM showed a significant increase in EBV DNA copy number compared to unstimulated cells, which was significantly reduced by co-culture with iguratimod. Nuclear expression of NF-κB was observed in AKATA cells stimulated with anti-human IgG, and NF-κB expression was suppressed by treatment with iguratimod. These findings suggest that iguratimod may reduce rheumatoid arthritis disease activity by partially inhibiting EBV reactivation. This may partially suppress the onset of RA.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-9"},"PeriodicalIF":2.3,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148707747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Divergent metabolic and immunoepigenetic responses in LPS-induced endotoxemia: a dose optimization study in male BALB/c mice. lps诱导的内毒素血症的不同代谢和免疫表观遗传反应：雄性BALB/c小鼠剂量优化研究

IF 2.3

Immunological Medicine Pub Date : 2026-08-10 DOI: 10.1080/25785826.2026.2715167

Yogi Prawira, Safarina G Malik, Zakiudin Munasir, Indah Suci Widyahening, Rismala Dewi, Anggraini Alam, Antonius H Pudjiadi

{"title":"Divergent metabolic and immunoepigenetic responses in LPS-induced endotoxemia: a dose optimization study in male BALB/c mice.","authors":"Yogi Prawira, Safarina G Malik, Zakiudin Munasir, Indah Suci Widyahening, Rismala Dewi, Anggraini Alam, Antonius H Pudjiadi","doi":"10.1080/25785826.2026.2715167","DOIUrl":"https://doi.org/10.1080/25785826.2026.2715167","url":null,"abstract":"Lipopolysaccharide (LPS)-induced endotoxemia is widely used to model sepsis. This study aimed to identify the LPS dose that reliably induces hyperlactatemia, Murine Sepsis Score (MSS) ≥3 (clinically defined sepsis), dose-dependent differences in 48-hour survival, and optimal histone H3K18 lactylation in male BALB/c mice. Sixty-six male BALB/c mice (8-10 weeks) received intraperitoneal LPS at doses of 1, 2.5, 5, 10, 15, and 20 mg/kgBW (N = 11 per group). Blood lactate was measured at 6 h, MSS was used to assess disease severity, and survival was monitored for 48 h. Peritoneal macrophages were isolated, and histone H3K18 lactylation normalized to total H3 (H3K18la/H3) was quantified. All groups developed hyperlactatemia (>4 mmol/L) without dose-dependent differences (p = 0.289). Meanwhile, MSS increased proportionally with LPS dose (ρ =  0.785; p= <0.001) and negatively correlated with lactate (ρ=-0.527; p = 0.025). Survival showed a general dose-related downward trend that did not reach significance, with a non-monotonic exception at 5 mg/kgBW. Macrophage yield varied across groups, while H3K18la/H3 levels were markedly elevated at LPS 15 and 20 mg/kgBW. To conclude, lactate rises early and non-uniformly across LPS doses, limiting its value as severity marker in male BALB/c endotoxemia. MSS provides a more dose-responsive indicator of clinical severity. An LPS dose of 15 mg/kg provides an optimal model for studying immunometabolic and immunoepigenetic responses in sepsis.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-17"},"PeriodicalIF":2.3,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148707736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cross-disease immunological comparison reveals shared systemic immune activation across the broader spondyloarthritis spectrum. 跨疾病免疫比较揭示了在更广泛的脊柱炎谱系中共享的系统性免疫激活。

IF 2.3

Immunological Medicine Pub Date : 2026-08-08 DOI: 10.1080/25785826.2026.2715176

Koichi Saito, Mitsuhiro Akiyama, Kanako Shimanuki, Waleed Alshehri, Takeru Maruyama, Takanori Sasaki, Keiko Yoshimoto, Noriyasu Seki, Hideto Tsujimoto, Kenji Chiba, Yuko Kaneko

{"title":"Cross-disease immunological comparison reveals shared systemic immune activation across the broader spondyloarthritis spectrum.","authors":"Koichi Saito, Mitsuhiro Akiyama, Kanako Shimanuki, Waleed Alshehri, Takeru Maruyama, Takanori Sasaki, Keiko Yoshimoto, Noriyasu Seki, Hideto Tsujimoto, Kenji Chiba, Yuko Kaneko","doi":"10.1080/25785826.2026.2715176","DOIUrl":"https://doi.org/10.1080/25785826.2026.2715176","url":null,"abstract":"To perform cross-disease immunological comparison across the broader spondyloarthritis (SpA) spectrum and examine their association with disease activity. We analyzed 111 patients with active broader SpA spectrum (ankylosing spondylitis, inflammatory bowel disease-associated SpA, psoriatic arthritis, pustulotic arthro-osteitis, and chronic non-bacterial osteitis) and 24 age- and sex-matched healthy controls (HC). Serum IL-17A, IL-17F, TNFα, and Oncostatin M levels were higher in the broader SpA spectrum than in HC. These cytokines levels did not differ among the broader SpA spectrum. Activated Th17, activated Th1-17, classical and intermediate monocytes were increased in the broader SpA spectrum compared with HC. Although Kruskal-Wallis test showed differences among the spectrum for activated Th17, activated Th1-17, and classical monocytes, post hoc analyses did not identify a specific disease driving these differences. Intermediate monocytes positively correlated with CRP and MMP-3 levels. Circulating immune subsets remained unchanged following DMARDs treatment despite clinical improvement. Systemic immune alterations, including activation of IL-17 axis, elevated Oncostatin M, and expansion of intermediate monocytes, are broadly shared across the broader SpA spectrum. Although global differences among the spectrum were observed for some immune cell populations, post hoc analyses did not identify disease-specific enrichment.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-13"},"PeriodicalIF":2.3,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148698042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low body weight as a risk factor for serious azathioprine-related adverse events in patients with rheumatic diseases. 低体重是风湿病患者严重硫唑嘌呤相关不良事件的危险因素

IF 2.3

Immunological Medicine Pub Date : 2026-07-29 DOI: 10.1080/25785826.2026.2701428

Shuhei Yoshida, Kiyoshi Migita, Tomoyuki Asano, Haruki Matsumoto, Shuzo Sato, Eiji Suzuki, Tomomi Sasajima, Masayuki Miyata, Michio Onizawa, Kazumichi Abe, Atsushi Takahashi, Yasuhiro Shimojima, Hiromasa Ohira

{"title":"Low body weight as a risk factor for serious azathioprine-related adverse events in patients with rheumatic diseases.","authors":"Shuhei Yoshida, Kiyoshi Migita, Tomoyuki Asano, Haruki Matsumoto, Shuzo Sato, Eiji Suzuki, Tomomi Sasajima, Masayuki Miyata, Michio Onizawa, Kazumichi Abe, Atsushi Takahashi, Yasuhiro Shimojima, Hiromasa Ohira","doi":"10.1080/25785826.2026.2701428","DOIUrl":"https://doi.org/10.1080/25785826.2026.2701428","url":null,"abstract":"Serious azathioprine (AZA)-related adverse events (AEs) contribute to treatment discontinuation in patients with rheumatic diseases, although real-world data on patient-related risk factors in Japanese patients remain limited. This study investigated predictive factors for serious AEs and their associations with patient characteristics in Japanese patients with rheumatic diseases. We previously conducted a nationwide questionnaire survey collecting clinical data from patients who initiated AZA treatment between November 2000 and September 2023, and performed a secondary analysis of these data. The incidence of serious AEs after AZA initiation and associations with patient characteristics were evaluated using univariable and multivariable analyses. Among 1,943 previously registered patients, body weight data were available for 1,824. AEs occurred in 618 patients (33.9%), including 47 (2.6%) with serious AEs. Multivariable analysis showed that older age (>66.5 years; odds ratio [OR] 1.98, 95% confidence interval [CI] 1.004-3.91) and lower body weight (BW) (<47.35 kg; OR 2.82, 95% CI 1.55-5.15) were significantly associated with serious AZA-related AEs. In subgroup analysis, low BW was significantly associated with serious AEs only in patients without NUDT15 codon 139 risk alleles. Older age and lower BW may help identify high-risk patients and support safer AZA use in Japanese patients with rheumatic diseases.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148608305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delayed glucocorticoid initiation is associated with lower stent removal rates in IgG4-related retroperitoneal fibrosis: a retrospective study. 在igg4相关的腹膜后纤维化中，延迟糖皮质激素起始与较低的支架移除率相关：一项回顾性研究。

IF 2.3

Immunological Medicine Pub Date : 2026-07-24 DOI: 10.1080/25785826.2026.2709284

Ken Nagahata, Masatoshi Kanda, Yuki Hamakawa, Koki Nakamura, Hidenori Amaike, Kuniyuki Aso, Hiroyuki Nakamura, Toshiaki Tanaka, Naoya Masumori, Hiroki Takahashi

{"title":"Delayed glucocorticoid initiation is associated with lower stent removal rates in IgG4-related retroperitoneal fibrosis: a retrospective study.","authors":"Ken Nagahata, Masatoshi Kanda, Yuki Hamakawa, Koki Nakamura, Hidenori Amaike, Kuniyuki Aso, Hiroyuki Nakamura, Toshiaki Tanaka, Naoya Masumori, Hiroki Takahashi","doi":"10.1080/25785826.2026.2709284","DOIUrl":"https://doi.org/10.1080/25785826.2026.2709284","url":null,"abstract":"IgG4-related retroperitoneal fibrosis (IgG4-related RPF) often causes hydronephrosis requiring ureteral stenting. While glucocorticoid (GC) therapy is generally effective, predictors of successful stent removal remain unestablished. This retrospective study investigated whether the interval from radiological diagnosis to GC initiation predicts stent-free outcomes. Twenty-one patients with IgG4-related RPF requiring ureteral stenting between April 2010 and December 2024 were categorized into stent-free (n = 12) and stent-dependent (n = 9) groups. Baseline serological markers (IgG, IgG4, and C-reactive protein) and renal function did not differ significantly between groups. However, the interval from radiological diagnosis to GC initiation was significantly shorter in the stent-free group compared to the stent-dependent group (median 110.5 vs. 264.0 days; p = 0.028). In the primary analysis, patients were dichotomized at the pre-specified cohort median of the diagnosis-to-GC interval (160 days), and Kaplan-Meier analysis showed that early initiation (≤ 160 days) was associated with a significantly higher stent removal rate (p = 0.031). An exploratory ROC analysis yielded a convergent optimal cutoff of 195 days (AUC 0.79; sensitivity 83%, specificity 78%). Delayed GC initiation may be associated with an increased risk of long-term stent dependence, suggesting the existence of a potential therapeutic window of approximately six months for achieving stent-free status.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148585272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rapidly enlarging intraocular inflammatory myofibroblastic tumor in an adult. 成人眼内迅速增大的炎性肌纤维母细胞瘤。

IF 2.3

Immunological Medicine Pub Date : 2026-07-11 DOI: 10.1080/25785826.2026.2701444

Taku Inamoto, Hiroyuki Komatsu, Kinya Tsubota, Masaki Asakage, Hiroshi Minato, Yoshitaka Utsumi, Toshitaka Nagao, Yoshihiko Usui

{"title":"Rapidly enlarging intraocular inflammatory myofibroblastic tumor in an adult.","authors":"Taku Inamoto, Hiroyuki Komatsu, Kinya Tsubota, Masaki Asakage, Hiroshi Minato, Yoshitaka Utsumi, Toshitaka Nagao, Yoshihiko Usui","doi":"10.1080/25785826.2026.2701444","DOIUrl":"https://doi.org/10.1080/25785826.2026.2701444","url":null,"abstract":"Intraocular inflammatory myofibroblastic tumor (IMT) is an extremely rare entity, and its clinical characteristics, immunopathological features, and optimal management remain insufficiently defined. A 57-year-old man presented with visual field defect in his right eye. Ophthalmic examination revealed an intraocular mass associated with retinal detachment. Magnetic resonance imaging and N-isopropyl-p-[123I] iodoamphetamine single photon emission computed tomography (123I-IMP-SPECT) demonstrated mild uptake suggestive of a malignant intraocular tumor, although differentiation from malignant melanoma remained difficult. The tumor exhibited rapid enlargement over a three-month period, leading to loss of light perception. Following enucleation, histopathological evaluation revealed proliferation of spindle-shaped tumor cells accompanied by prominent inflammatory cell infiltration. Immunohistochemical analysis demonstrated diffuse and strong positivity for anaplastic lymphoma kinase (ALK). Fluorescence in situ hybridization (FISH) for ALK rearrangement yielded equivocal results. Based on an integrated assessment of clinicopathological and immunohistochemical findings, a final diagnosis of intraocular IMT was deemed most appropriate. Intraocular IMT should be considered in the differential diagnosis of rapidly progressive intraocular tumors. Accurate diagnosis requires comprehensive clinicopathological correlation, including detailed immunohistochemical evaluation. Given the potential aggressive clinical behavior despite its inflammatory nature, timely surgical intervention may be necessary for both diagnostic confirmation and disease control.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-6"},"PeriodicalIF":2.3,"publicationDate":"2026-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148425014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early steroid initiation may improve outcomes in immune checkpoint inhibitor-related cholangitis: a multicenter cohort study. 早期使用类固醇可能改善免疫检查点抑制剂相关胆管炎的预后：一项多中心队列研究

IF 2.3

Immunological Medicine Pub Date : 2026-07-06 DOI: 10.1080/25785826.2026.2699469

Mayuko Kondo, Keisuke Ojiro, Makoto Ueno, Yukie Nakadai, Takaya Tabuchi, Ryosuke Kasuga, Hitomi Hoshi, Akihiro Yamaguchi, Chu Po-Sung, Nobuhito Taniki, Shingo Usui, Takanori Kanai, Nobuhiro Nakamoto

{"title":"Early steroid initiation may improve outcomes in immune checkpoint inhibitor-related cholangitis: a multicenter cohort study.","authors":"Mayuko Kondo, Keisuke Ojiro, Makoto Ueno, Yukie Nakadai, Takaya Tabuchi, Ryosuke Kasuga, Hitomi Hoshi, Akihiro Yamaguchi, Chu Po-Sung, Nobuhito Taniki, Shingo Usui, Takanori Kanai, Nobuhiro Nakamoto","doi":"10.1080/25785826.2026.2699469","DOIUrl":"10.1080/25785826.2026.2699469","url":null,"abstract":"Immune-checkpoint inhibitor (ICI)-related cholangitis is a rare but potentially fatal immune-related adverse event. In this study, we retrospectively analyzed 11 patients diagnosed with ICI-related cholangitis between 2020 and 2024 at Keio University Hospital and three affiliated hospitals. The diagnosis was based on alkaline phosphatase (ALP) elevation ≥ Common Terminology Criteria for Adverse Events Grade 2, in combination with characteristic imaging findings of bile duct dilatation or wall thickening without obstruction, after excluding other etiologies. The median ALP at onset was 437 IU/L, rising to 1304 IU/L at its peak. Total bilirubin (TB) increased from a median of 1.4 to 4.8 mg/dL during the clinical course, and worsening jaundice was observed in all fatal cases, suggesting TB as a potential prognostic indicator. All patients received steroid therapy, and seven required additional immunosuppressants, of whom six achieved at least a partial ALP response. Overall, three patients died of ICI-related cholangitis and two of the underlying malignancy. Early initiation of steroids (≤18 days from onset) was associated with reduced ICI-related mortality (p = 0.04). These findings underscore the importance of early recognition, timely initiation of steroids, and careful monitoring of bilirubin levels as a prognostic indicator in ICI-related cholangitis.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors for adverse events or use of high-potency corticosteroids in non-infectious uveitis: a Japan claims database study (J-CAT2). 非感染性葡萄膜炎中使用高效皮质类固醇或不良事件的危险因素：一项日本索赔数据库研究（J-CAT2）

IF 2.3

Immunological Medicine Pub Date : 2026-07-04 DOI: 10.1080/25785826.2026.2693410

Sentaro Kusuhara, Koh-Hei Sonoda, Toshikatsu Kaburaki, Tachie Fujita, Saki Katayama, Misako Makishima, Takao Nakamura, Mariko Nio, Takashi Omoto, Yukari Matsuo-Tezuka, Tomoki Yoshizaki, Mio Kitamura, Kensuke Sasaki, Kairi Ri, Keiko Sato, Hiroshi Goto

{"title":"Risk factors for adverse events or use of high-potency corticosteroids in non-infectious uveitis: a Japan claims database study (J-CAT2).","authors":"Sentaro Kusuhara, Koh-Hei Sonoda, Toshikatsu Kaburaki, Tachie Fujita, Saki Katayama, Misako Makishima, Takao Nakamura, Mariko Nio, Takashi Omoto, Yukari Matsuo-Tezuka, Tomoki Yoshizaki, Mio Kitamura, Kensuke Sasaki, Kairi Ri, Keiko Sato, Hiroshi Goto","doi":"10.1080/25785826.2026.2693410","DOIUrl":"https://doi.org/10.1080/25785826.2026.2693410","url":null,"abstract":"The J-CAT2 study (#jRCT1030240195) aimed to evaluate treatment and patient factors associated with risk of complications/adverse events (AEs) or high corticosteroid exposure in patients with non-infectious uveitis (NIU) using advanced quantitative and visual analytical approaches. The study included data from a nationwide insurance claims database in Japan. Patients with NIU treatment-related claims (2016-2023) were included (n = 98,842). A nested case-control design was used to evaluate patient factors associated with complications/AEs or high corticosteroid exposure. Multivariable logistic regression and decision-tree analyses were performed. Sub-Tenon's corticosteroid injections were associated with dose-dependent increased odds of glaucoma treatment and cataract surgery (OR [95% CI]: 1 sub-Tenon's injection, 3.27 [2.60-4.11] and 3.19 [2.39-4.27], respectively; ≥2 sub-Tenon's injections, 5.54 [4.03-7.60] and 4.86 [3.44-6.85], respectively). Macular edema was the most likely factor associated with ≥2 sub-Tenon injections. Vogt-Koyanagi-Harada disease and sarcoidosis were the most likely factors associated with medium-to-high-dose corticosteroids and long-term oral corticosteroids. The J-CAT2 study used a novel, quantitative and visual framework to understand associations between dose, frequency, and duration of corticosteroid treatment and complications/AE risk in NIU. These findings suggest that optimization of corticosteroid administration protocols and exploration of alternative therapeutic strategies/targeted treatment approaches are necessary to mitigate complication risks.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-18"},"PeriodicalIF":2.3,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148388234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Achievement of intermediate treatment targets for Still's disease under tocilizumab treatment: a post-hoc analysis of the phase III trial. tocilizumab治疗斯蒂尔氏病的中间治疗目标的实现：III期试验的事后分析

IF 2.3

Immunological Medicine Pub Date : 2026-06-26 DOI: 10.1080/25785826.2026.2694145

Koji Suzuki, Hideto Kameda, Kei Ikeda, Tomonori Ishii, Kosaku Murakami, Hyota Takamatsu, Yoshiya Tanaka, Takayuki Abe, Tsutomu Takeuchi, Yuko Kaneko

{"title":"Achievement of intermediate treatment targets for Still's disease under tocilizumab treatment: a post-hoc analysis of the phase III trial.","authors":"Koji Suzuki, Hideto Kameda, Kei Ikeda, Tomonori Ishii, Kosaku Murakami, Hyota Takamatsu, Yoshiya Tanaka, Takayuki Abe, Tsutomu Takeuchi, Yuko Kaneko","doi":"10.1080/25785826.2026.2694145","DOIUrl":"https://doi.org/10.1080/25785826.2026.2694145","url":null,"abstract":"To evaluate the intermediate treatment targets for Still's disease proposed by EULAR/PReS recently, we conducted this post-hoc analysis of the Phase III trial of tocilizumab and its long-term extension to assess the achievement probability of these targets with tocilizumab. Additionally, we assessed the associations of the intermediate treatment targets with long-term outcomes, including glucocorticoid-free clinically inactive disease (CID) and recurrence. Given the predefined glucocorticoid tapering schedule, we also evaluated the achievement of CID irrespective of glucocorticoid dosage when assessing treatment targets at Months 3 and 6. Twenty-one patients were followed for a median of 39.8 months. The week 4 target was achieved in 57.1%, while 47.6% and 38.1% achieved CID at months 3 and 6, respectively. At the final visit, 57.1% and 28.6% achieved CID and glucocorticoid-free CID, respectively. Achievement of the week 4 target and CID at month 6 was associated with subsequent glucocorticoid-free CID (50% vs. 0%, p = 0.01; 62.5% vs. 7.7%, p = 0.01). Month 6 CID achievers had higher baseline swollen joint counts and lower interferon-γ levels. In conclusion, achievement of intermediate treatment targets was associated with long-term CID, suggesting that these targets may also be useful in treatment with tocilizumab.Clinical trial registration: UMIN000012987, UMIN000018414.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148340566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0